Literature DB >> 32229190

Oncogenic HBV variants and integration are present in hepatic and lymphoid cells derived from chronic HBV patients.

Keith Ck Lau1, Shivali S Joshi1, Shan Gao1, Elizabeth Giles2, Ken Swidinsky2, Guido van Marle3, Oliver F Bathe4, Stefan J Urbanski5, Norah A Terrault6, Kelly W Burak7, Carla Osiowy2, Carla S Coffin8.   

Abstract

The hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC), partly driven by viral integration and specific oncogenic HBV variants. However, the biological significance of HBV genomes within lymphoid cells (i.e., peripheral blood mononuclear cells, PBMCs) is unclear. Here, we collected available plasma, PBMC, liver, and tumor from 52 chronic HBV (CHB) carriers: 32 with HCC, 19 without HCC, and one with dendritic cell sarcoma, DCS. Using highly sensitive sequencing techniques, next generation sequencing, and AluPCR, we demonstrate that viral genomes (i.e., HBV DNA, RNA, and cccDNA), oncogenic variants, and HBV-host integration are often found in all sample types collected from 52 patients (including lymphoid cells and a DCS tumor). Viral integration was recurrently identified (n = 90 such hits) in genes associated with oncogenic consequences in lymphoid and liver cells. Further, HBV genomes increased in PBMCs derived from 7 additional (treated or untreated) CHB carriers after extracellular mitogen stimulation. Our study shows novel HBV molecular data and replication not only liver, but also within 63.8% of lymphoid cells analysed (including a representative lymphoid cell malignancy), that was enhanced in ex vivo stimulated PBMC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extrahepatic malignancy; Hepatocellular carcinoma; Oncogenesis; Single nucleotide polymorphisms; Viral integration; Viral reservoirs

Mesh:

Substances:

Year:  2020        PMID: 32229190     DOI: 10.1016/j.canlet.2020.03.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.

Authors:  Keith C K Lau; Shivali S Joshi; Douglas J Mahoney; Andrew L Mason; Guido van Marle; Carla Osiowy; Carla S Coffin
Journal:  Front Microbiol       Date:  2020-07-14       Impact factor: 5.640

Review 2.  Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 3.  Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma.

Authors:  Simmone D'souza; Keith Ck Lau; Carla S Coffin; Trushar R Patel
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

4.  Editorial: Novel Concepts in Mechanisms Modulating HBV Persistence, Pathogenesis, and Oncogenetic Properties.

Authors:  Valentina Svicher; Loredana Sarmati
Journal:  Front Microbiol       Date:  2021-12-24       Impact factor: 5.640

Review 5.  The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma.

Authors:  Yi Shi; Ji-Bin Liu; Jing Deng; Da-Zhi Zou; Jian-Jun Wu; Ya-Hong Cao; Jie Yin; Yu-Shui Ma; Fu Da; Wen Li
Journal:  Hereditas       Date:  2021-11-10       Impact factor: 3.271

Review 6.  Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure.

Authors:  Romina Salpini; Stefano D'Anna; Livia Benedetti; Lorenzo Piermatteo; Upkar Gill; Valentina Svicher; Patrick T F Kennedy
Journal:  Front Microbiol       Date:  2022-09-02       Impact factor: 6.064

7.  Chronic Hepatitis B Viral Activity Enough to Take Antiviral Drug Could Predict the Survival Rate in Malignant Lymphoma.

Authors:  Kwang-Il Seo; Jae-Cheol Jo; Da-Jung Kim; Jee-Yeong Jeong; Sangjin Lee; Ho-Sup Lee
Journal:  Viruses       Date:  2022-08-31       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.